These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12241559)

  • 1. The average cost of measles cases and adverse events following vaccination in industrialised countries.
    Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
    BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost of measles in industrialised countries.
    Carabin H; Edmunds WJ; Gyldmark M; Beutels P; Lévy-Bruhl D; Salo H; Griffiths UK
    Vaccine; 2003 Oct; 21(27-30):4167-77. PubMed ID: 14505896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
    Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
    Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future savings from measles eradication in industrialized countries.
    Carabin H; Edmunds WJ
    J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
    Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
    Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
    PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
    Wichmann O; Ultsch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic disease burden of measles in Japan and a benefit cost analysis of vaccination, a retrospective study.
    Takahashi K; Ohkusa Y; Kim JY
    BMC Health Serv Res; 2011 Oct; 11():254. PubMed ID: 21978107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
    Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles control in developing and developed countries: the case for a two-dose policy.
    Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
    Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
    Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
    Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of measles treatment: a systematic review.
    Vo NX; Van Nguyen AT; Mai Tran HT; Thuy Truong LT; Bao Nguyen NN
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S148-S154. PubMed ID: 31369545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
    Dayan GH; Cairns L; Sangrujee N; Mtonga A; Nguyen V; Strebel P
    Vaccine; 2004 Jan; 22(3-4):475-84. PubMed ID: 14670330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of the current measles vaccination program: A case study in Zhejiang Province, east China.
    Zeng Y; Luo M; Chen J; He H; Deng X; Xie S; Fang Y
    Vaccine; 2019 May; 37(23):3071-3077. PubMed ID: 31040084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of measles control during elimination in Ontario, Canada, 2015.
    Ramsay LC; Crowcroft NS; Thomas S; Aruffo E; Teslya A; Heffernan JM; Gournis E; Hiebert J; Jaeger V; Jiaravuthisan M; Sharron J; Severini A; Deeks SL; Gubbay J; Mazzulli T; Sander B
    Euro Surveill; 2019 Mar; 24(11):. PubMed ID: 30892178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of second measles containing vaccine (MCV) dose: a systematic review of available evidence.
    Bawa S; Wondimu A; Postma MJ; Hutubessy R; van Hulst M
    Expert Rev Vaccines; 2024; 23(1):655-673. PubMed ID: 38924461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.